Nykode Therapeutics AS (STU:5VB) Total Stockholders Equity: €75.70 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:5VB Nykode Therapeutics AS STU:5VB
38 GF Score
Price €0.29
GF Value €0.55
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Nykode Therapeutics AS Total Stockholders Equity?

Nykode Therapeutics AS STU:5VB +0.35% 38 Total Stockholders Equity is €75.70 Mil as of Mar. 2026. GuruFocus rates STU:5VB with a GF Score™ of 38/100 and a GF Value™ of €0.55 (Possible Value Trap). The stock has 2 warning signs investors should review.

Nykode Therapeutics AS's Total Stockholders Equity for the quarter that ended in Mar. 2026 was €75.70 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Nykode Therapeutics AS's Book Value per Share for the quarter that ended in Mar. 2026 was €0.23. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Nykode Therapeutics AS's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.03.

Nykode Therapeutics AS  (STU:5VB) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Nykode Therapeutics AS's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(75.699-0)/326.546
=0.23

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Nykode Therapeutics AS's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.126 + 0.891) / 75.699
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nykode Therapeutics AS Total Stockholders Equity Related Terms

Nykode Therapeutics AS Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Nykode Therapeutics AS's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nykode Therapeutics AS Total Stockholders Equity Chart

Nykode Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only 171.74 148.23 157.05 130.08 78.17

Nykode Therapeutics AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 123.90 89.10 84.56 78.17 75.70
STU:5VB
38GF Score
Nykode Therapeutics AS STU:5VB
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of €75.70 Mil mean?
Nykode Therapeutics AS (STU:5VB) has a Total Stockholders Equity of €75.70 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Nykode Therapeutics AS and its competitors.
Is Nykode Therapeutics AS's Total Stockholders Equity too high?
Nykode Therapeutics AS's current Total Stockholders Equity is €75.70 Mil. Overall, Nykode Therapeutics AS has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Total Stockholders Equity compare to VRTX and REGN?
Nykode Therapeutics AS's Total Stockholders Equity of €75.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Nykode Therapeutics AS and its competitors. Nykode Therapeutics AS's current Total Stockholders Equity is €75.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (STU:5VB) is currently considered Possible Value Trap. The stock's GF Value™ is €0.55, compared to a current price of €0.29 — trading 48% below its estimated fair value. The current Total Stockholders Equity is €75.70 Mil. Nykode Therapeutics AS's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Nykode Therapeutics AS (STU:5VB), the current Total Stockholders Equity is €75.70 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nykode Therapeutics AS (STU:5VB) Overvalued in 2026?

Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued. The current stock price of €0.29 is trading 48% below its estimated GF Value™ of €0.55. GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.

Key valuation signals for STU:5VB:

  • Total Stockholders Equity: €75.70 Mil
  • GF Value™: €0.55 vs. price of €0.29 (48% below fair value)
  • GF Score™: 38/100 with 2 warning signs

No single metric tells the full story. See the STU:5VB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nykode Therapeutics AS Business Description

Address Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
38GF Score

Get the complete analysis for STU:5VB

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.29
Price
€0.55
GF Value